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Abstract
Detailed DNA sequencing of the triple-helical domain of type
III procollagen was carried out on cDNA prepared from 54
patients with aortic aneurysms. The 43 male and 11 female
patients originated from 50 different families and five different
nationalities. 43 patients had at least one additional blood rela-
tive who had aneurysms. Five overlapping asymmetric PCR
products, covering all the coding sequences of the triple-helical
domain of type III procollagen, were sequenced with 28 specific
sequencing primers. Analysis of the sequencing gels revealed
only two nucleotide changes that altered the structure of the
protein. One was a substitution of threonine for proline at
amino acid position 501 and its functional importance was not
clearly established. The other was a substitution of arginine for
an obligatory glycine at amino acid position 136. In 40 ofthe 54
patients, detection of a polymorphism in the mRNA estab-
lished that both alleles were expressed. The results indicate
that mutations in type III procollagen are the cause of only
about 2% of aortic aneurysms. (J. Clin. Invest. 1993. 91:2539-
2545.) Key words: familial aneurysms * polymerase chain reac-
tion- polymorphisms
Introduction
A number of careful studies have shown that aneurysms, even
when they are not associated with well-recognized, heritable
syndromes such as the Marfan syndrome ( 1 ) or Ehlers-Danlos
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syndrome (EDS)' type IV ( 1 ), are frequently familial (2-1 1 ).
A recent statistical evaluation suggested that aneurysms are
caused by defects in a single gene ( 12). The structural compo-
nents of arteries and the gene products participating in the
proteolysis of the structural components have been suggested
as candidate genes for aneurysms ( 13 ). Mutations in the fibril-
lin gene located in chromosome 15 (14) have been shown to
cause the Marfan syndrome ( 15, 16). There is a considerable
variability in the phenotype among different individuals with
the Marfan syndrome within the same family and among dif-
ferent families ( 17). Fibrillin 15 is, therefore, a potential candi-
date gene for aortic aneurysms ( 17). Other candidate genes for
aortic aneurysms are collagens and elastin, which are impor-
tant structural components of the aorta. Their contribution to
the strength ofan artery was elegantly demonstrated by Dobrin
and his co-workers ( 18) by using dog and human cadaver arter-
ies in a system where pressure could be applied onto the artery.
Treatment of the artery with collagenase or elastase resulted in
a considerable weakness ofthe structure ( 18). Several different
types of collagens have been isolated from blood vessels, but
types I and III collagen are the major components in the arte-
rial wall ( 19). They are fibril-forming collagens in which three
polypeptide chains called the a chains form a stable triple-heli-
cal structure (20, 21 ). Each a chain consists of about 340 re-
peating tripeptide sequences of -Gly-X-Y- in which X is fre-
quently proline and Y is frequently hydroxyproline (20, 21 ). A
recent study on the type III procollagen secreted by cultured
skin fibroblasts from patients with aortic aneurysms demon-
strated that in 2 out of 14 patients the type III procollagen was
thermally unstable when assayed by brief proteinase digestion,
suggesting a structural defect in the type III procollagen (22).
Furthermore, a mutation in the type III procollagen gene was
found in a man who expired at the age of 34 yr from a rupture
of the aorta (23). The man had a history of easy bruisability
and bleeding, but none of the dramatic skin changes usually
associated with type IV EDS ( 1, 24) such as ecchymoses, ab-
normal scarring, and heavy pigmentation (23). He, therefore,
1. Abbreviations used in this paper: EDS, Ehlers-Danlos syndrome; nt,
nucleotide.
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probably presented phenotypic overlap between EDS type IV
and familial aneurysms. Subsequently, a mutation in the type
III procollagen gene was found in a 37-yr-old woman who had
a strong family history of sudden death from ruptured aortic
aneurysms (25) without any evidence of EDS type IV or re-
lated disorder.
The hypothesis that aortic aneurysms are caused by in-
creased proteolytic activity in the aorta that leads to the weaken-
ing ofthe arterial wall and rupture, has also been supported by
several studies (26-29). There are, however, very few, if any,
known examples of a gene defect producing an increase in an
enzyme activity. It might, therefore, be that the increased pro-
teolytic activity found in aneurysmal aorta is a secondary phe-
nomenon due to some other primary defect.
In conclusion, several candidate genes for aortic aneurysms
have been suggested, including (a) fibrillin 15 (17), (b) colla-
gen (20, 21, 30), (c) elastin (31), (d) collagenase (18), (e)
elastase (27), (f) tissue inhibitor of metalloproteinase (29),
and (g) a1-antitrypsin (28). In this article we report the de-
tailed DNA sequencing approach to answer the question of
whether most aneurysms are caused by mutations in the gene
for the type III procollagen.
Methods
Patient material. Skin biopsy was obtained from all patients listed in
Table I after written informed consent. In some cases, blood samples
were obtained from family members of the patient after written in-
formed consent. Skin biopsies were used to establish skin fibroblast
cultures. Total RNA was isolated from cultured skin fibroblasts with a
procedure involving extraction with guanidinium isothiocyanate (32).
The RNA was purified by centrifugation on a cesium chloride gradient
and used to synthesize first strand ofcDNA with MMVL reverse tran-
scriptase (Bethesda Research Laboratories, Gaithersburg, MD). Geno-
mic DNA was isolated from cultured skin fibroblasts or blood on a
Genepure 341 automated DNA extractor (Applied Biosystems, Inc.,
Foster City, CA).
Sequencing ofcDNA. Sets of oligonucleotides (Table II) based on
the cDNA sequence of type III procollagen (33-38) were used as
primers so as to generate five overlapping PCR products ( 1, 2A, 2B, 3,
and 4 in Table II) to cover all the coding sequences for the triple-helical
domain of 1029 amino acids of the type III procollagen. Originally,
products 2A and 2B were amplified together as one longer fragment,
but since results from DNA sequencing were somewhat variable, the
region was divided into two PCR fragments, after which the sequencing
results improved. To produce single-stranded DNA sequencing tem-
plates, three successive PCRs, of 20 cycles each, were performed for
each region.
The first PCR (39) was carried out for 20 cycles in a 30-pl reaction
volume containing 0.6 pmol of each primer. 2 ql of the first PCR
product was used in a second PCR that was carried out for 20 cycles in a
50 pl-reaction volume containing 10 pmol ofone primer and 2.5 pmol
of the other. The third PCR was carried out for 20 cycles in a 100 p1
reaction volume containing 50 pmol of one primer and 1 pmol of the
other primer and 2 ,l of the second PCR product. The products from
the third PCR were run on an agarose gel, and ifthey were ofacceptable
quality, additional third PCRs were performed to produce sufficient
template DNA for sequencing.
Typically, the final results from the third PCR showed a clean am-
plification ofthe desired product on an agarose gel with two bands, one
representing the double-stranded DNA and the other representing the
single-stranded DNA (not shown). Routinely, cDNA from 10 differ-
ent cell lines was amplified simultaneously. Water blanks were in-
cluded in every experiment and they were negative.
The PCR products were purified by adsorption to powdered glass
(silica) under high salt conditions using a commercial kit (Geneclean,
BIO 101, Inc., Vista, CA). Since adsorption ofDNA to silica powder in
the presence of 6 M Nal is pH-dependent (pH of 6 M Nal should be
between 6.2 and 7.2 at room temperature), the Nal solution was buff-
ered with 50mM Pipes and the pH was adjusted to 6.7 at room tempera-
ture with acetic acid. In addition, the pH of the asymmetric PCR sam-
ple was modified by the addition of 1 Al of I M Pipes, pH 6.7, per 100 A1
of PCR product. Successful asymmetric PCRs were transferred to mi-
crocentrifuge tubes and three volumes of pH-buffered Nal and 5 JA1 of
"Glassmilk" per 100 pl of PCR product were added and the mixtures
rotated at room temperature. Pelleting and washing of the powdered
glass were performed according to the Geneclean kit instructions ex-
cept that they were performed in an Autogen 540 (an integrated micro-
centrifuge and pipetting station; Autogen Instruments Inc., Beverly,
MA). The pellet was air-dried for 10 min at room temperature after the
final wash and the adsorbed DNA eluted by resuspending the pellet in
5-30 pAl of water and heating to 650C for 10 min. The powdered glass
was pelleted by 20 min centrifugation and the supernatant transferred
to a new tube. Because adsorption of nucleic acids to powdered glass
(under the conditions used here) is dependent on length with ex-
tremely inefficient adsorption of fragments less than 300 nt in length,
the purified asymmetrical PCR products contained almost no PCR
primers and were suitable to use as templates in dideoxynucleotide
DNA sequencing.
The purified PCR products were sequenced directly with 28 se-
quencing primers specific for type III collagen (Table III) using Se-
quenase (U.S. Biochemical Corp., Cleveland, OH) or Taq DNA poly-
merase (Perkin Elmer Cetus, Norwalk, CT) in the dideoxynucleotide
method (40). The sequencing was carried out in sets of 12 so that DNA
from 10 different cell lines, M 13 control DNA and M 13 clone contain-
ing type III collagen sequences that corresponded to the region in the
patient sample, were sequenced simultaneously on a multiwell plate
(Earley and Tromp, manuscript in preparation). The reactions were
run on 6% DNA sequencing gels (Sequagel-6, National Diagnostics,
Atlanta, GA). To increase the speed and ease with which the autoradio-
graphs could be interpreted, several reactions terminated with the same
dideoxynucleotide were loaded in adjacent lanes (Fig. 1). Typically,
the samples from 5-10 patients were loaded so that the blocks of adja-
cent lanes could be interpreted like a conventional sequence ladder. A
significant advantage was that it was easy to identify the appearance of
a new band where the other cell lines lacked the band.
Analysis ofDNA polymorphisms. Three polymorphic bases at posi-
tions nucleotides (nt) 1851, 2092, and 2244 in the coding region of
type III collagen were analyzed using genomic DNA as a template in
the PCR according to conditions described previously (41, 42; Wu and
Kuivaniemi, manuscript in preparation). PCR products were then an-
alyzed using allele-specific oligonucleotide hybridization technique or
restriction endonuclease digestion as described previously (41, 42; Wu
and Kuivaniemi, manuscript in preparation).
Results
Patient material. DNA sequencing was carried out on type III
collagen cDNA from 54 patients with aneurysms. Among the
54 patients there were four pairs of siblings (JIMM408 and
JIMM409, JIMM425 and JIMM425a, JIMM425b and
JIMM425c, and JIMM425d and JIMM425e in Table I). Thus,
the number of unrelated individuals analyzed was 50, repre-
senting 50 different families. The 50 unrelated patients were
from five different nationalities: 1 Haitian, 3 Finnish, 4 Cana-
dian, 11 Swedish, and 31 U.S. American. Most (43/50) ofthe
patients had at least one blood relative who was also diagnosed
with an aneurysm. More specifically, 15 patients had one fam-
ily member with the disease, 17 patients had two family
members, 6 patients had three family members, 2 patients had
2540 Tromp et al.
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Table I. Clinical Information on Patients
Location of
Code Gender Age* aneurysmt Status1 Family"l Nationality
JIMM255 M 60 AAA R 3 (2B,A)' Swedish
JIMM256 M 64 AAA, IA 0, R 1(F) Swedish
JIMM263 M 38 TAA CT 0 Canadian
JIMM279 F 50 IA 0 2 (5, N)' Swedish
JIMM280 M 55 AAA 0 0 Swedish
JIMM281 M 60 AAA 0 0 Swedish
JIMM285 M 54 AAA, 11A 0 1 (B) U.S.
JIMM295 M 55 AAA, IA 0, R 2 (2B)' Swedish
JIMM296 M 68 AAA 0 0 Swedish
JIMM332 M 70 AAA 0 0 Swedish
JIMM334 F 67 AAA 0 1 (B) U.S.
JIMM335 M 69 AAA 0 1 (B) U.S.
JIMM335d M 65 AAA 0 1 (B) U.S.
JIMM335f M 67 AAA 0 2 (2S) U.S.
JIMM335g M 66 AAA 0 2 (2B) U.S.
JIMM335h M 64 AAA 0 1 (B) U.S.
JIMM335i M 73 AAA 0 2 (B, 5) U.S.
JIMM335j M 67 AAA 0 1 (B) U.S.
JIMM335k M 65 AAA 0 2 (B, 5) U.S.
JIMM341 M 73 AAA 0 1 (5) Swedish
JIMM342 M 46 AAA, IA 0, R 2 (S, F)' Swedish
JIMM350 M 66 AAA 0 1 (B) Swedish
JIMM35 1 F 62 TAA R 2 (F, 5) U.S.
JIMM396 M 58 AAA, IIA 0 2 (F, B) U.S.
JIMM397 M 67 AAA 0 3 (B, 2C) Finnish
JIMM398 M 66 AAA U 1(B) Finnish
JIMM406 M 41 MAA 0 2 (D, B) U.S.
JIMM407 M 18 AAA R U.S.
JIMM408 M 68 AAA - (F, G, A, 2B) U.S.
JIMM409 M 63 AAA - (F, G, A, 2B) U.S.
JIMM419 M 59 AAA R 3 (F, 2C) U.S.
JIMM421 F 47 AAA 0 4 (2B, M, F) U.S.
JIMM422 F 85 AAA 0 3 (2B, F) U.S.
JIMM425 M 70 AAA U 1(B) Canadian
JIMM425a M 71 AAA 0 1 (B) Canadian
JIMM425b M 65 AAA 0 2 (B) Canadian
JIMM425c M 62 AAA 0 2 (B) Canadian
JIMM425d M 69 AAA 0 1 (B) Canadian
JIMM425e M 70 AAA U 1(B) Canadian
JIMM425g F 65 AAA U 1(B) Canadian
JIMM429 F 77 AAA - 2 (2S) U.S.
JIMM430 M - AAA 0 9 (4B, 5, 2A, 2C) U.S.
JIMM436 M 40 IA 0 4 (S, F, C, U) U.S.
JIMM438 M 63 AAA 0 1 (B) U.S.
JIMM443 F 34 AAA 0 3 (2B3, M)' U.S.
JIMM445 F 68 AAA 0 2 (F, 5) U.S.
JIMM449 M 59 AAA 0 2 (B, M) U.S.
JIMM483 F 76 AAA U 2 (B, 5) U.S.
JIMM490 M 49 TAA R 13 (6C, 2S, B, G, 2A, U) U.S.
JIMM492 M 79 AAA 0 1 (B) U.S.
JIMM497 F 73 TAA 0 3 (3B)' U.S.
JIMM498 M 71 AAA 0 2 (F, N)' U.S.
JIMM499 M 46 IA, TAA 0, R 0 Haitian
JIMM543 M 25 TAA R 2 (F, 0) Finnish
*At the time of diagnosis.
Abbreviations: AAA, abdominal aortic aneurysm; TAA, thoracic aortic aneurysm; MAA, multiple aortic aneurysms; IIA, iliac artery aneurysm; IA, intracranial
artery aneurysm.
Sttsof aneurysm at the time of diagnosis. Abbreviations: U, dilation detected by ultrasonography; 0, elective operation; R, rupture; CT, computerized tomography.
"Number of affected family members in addition to the proband. Abbreviations: 5, sister, B, brother, F, father-, M, mother-, D, daughter, So, son; G, grandparent; C,
cousin; U, uncle; A, aunt; N, niece or nephew.
'Some members in the family have intracranial aneurysms.
four family members, 1 patient had five family members, 1I 60.3±14.1). Among the 54 patients studied there were 43
patient had nine family members, and another patient had 13 males and 11I females. The males were between 18 and 79 yr of
affected family members. The age of the patients at the time age at the time of diagnosis (mean±SD = 59.3±13.9). The
of diagnosis varied between 18 and 85 yr (mean±SD females were between 34 and 85 yr ofage at the time ofdiagno-
Aortic Aneurysms and Type III Procollagen Gene 2541
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Table II. Oligonucleotide Primers Used to Amplify the Coding Sequences ofthe al(III) Triple-Helical Domain
PCR Primer Primer Size of
product name Primer sequence location* PCR product
bp
1 III-1 GCCGTCTAGACTGGTCCTCAGAACTATTCT 436-456 1026
111-2 CGCAAGCTTAGCTCCTGGAAGCCCATTTGC 1423-1443
2A III-3 GCCGTCTAGAAGAATGGTGCCAAAGGAGAG 1305-1326 688
III-32 CGCGAATTCTTCCCCAGGTTTTCCATTTTCT 1954-1974
2B III-25 CGCGGATCCAGTCAAGGATAAAGTGGTCGA 1666-1686 562
111-4 CGCAAGCTTGACTTCCAAGACCTCCTCTTT 2189-2209
3 111-5 GCCTCTAGACCACAAGGATTACAAGGCTTG 1909-1929 1067
III-6 CCCGCAAGCTTAGCTCCTGGTTTCCCACTTT 2936-2955
4 111-13 CGGAATTCTTGGGATTGCTGGGATCACT 2839-2859 933
111-14 CGGAATTCATCAGGACTAATGAGGCTTTC 3736-3757
* Location in cDNA sequence, nucleotide numbers according to Ala-Kokko et al. (36).
sis (mean±SD = 63.3±15.0), and all females had at least one study because they had family members with aortic aneurysms.
additional blood relative who had the disease. One ofthese cases was JIMM279 who had an intracranial aneu-
A majority (46 of 54) of the patients had aneurysm(s) in rysm at the age of 50 yr and whose sister also had an intracra-
the abdominal aorta (see Table I). There were, however, six nial aneurysm and the daughter of the sister had a dissecting
patients with a thoracic aortic aneurysm. In addition, three aortic aneurysm at the age of 25 yr.
patients with intracranial aneurysms were included in the Four patients had aneurysms both in cranial arteries and in
Table III. Oligonucleotide Primers Usedfor Direct Sequencing ofthe PCR Products
PCR product Primer name Primer sequence
1 SP38 CTT GCC ATC TTC GCC TTT AGC T
SP12B CTC CTT TGG CAC CAT TCT TA
FS8 ACC CAT TTC GCC TTT AC
FS2 GCC TTC GAA TTG TCC AGG GGC ACC ATT TGA
SP41 CCT CGA GCA CCG TCA TTA
SP 1I CAT TTC GTC CAT CGA AG
SP22 CTA CCT GAT TCT CAA TCT TTT
IR JEJ-1 CCT GGA CTG ATG GGA GCC CG
2A SP36 TGT GTC TCC TII GTC ACC ACC A
SP39 GCC ACC TCG TTC TCC ATT CTT A
SP2 CGG GCA TGC CCC TCA TT
SP13B CAC 1-' CTC CTT GAC TT
2B ALA2194 GGG GAC CAG CTC CAC CTC T
SP9 CAA GCC TTG TAA TCC TT
3 SP40 ACT TTC ACC CTT GAC ACC CTG A
SP15B GCA CCA GGC GAT CTC TTC TCT
SP30 CCT GGG TTA CCA TTA CTA CC
SP4 GGG CCT CCT TCA CCT TT
SP31 CCA GTT TCA CCT CTC TCA C
SP19 GAC TTC CAA GAC CTC CTC TTT C
SP14 CAC CCT TTC CTC CTT CG
4 SP42 CTA ATG AGG CTT TCT ATT TGT
SP16 ATG GCA GCG GCT CCA AC
SP43 CCT GGG GAG CCC TCA GAT
SP17 CCG ATT GCA CCC TGC TG
SP7 CTG TTT CAC CTT TGT
SP33 ACC ACG ATC ACC CTT GCC A
SP44 TCC AGG TTC ACC AGC TGT A
2542 Tromp et al.
The PCR product number refers to the numbers presented in Table II. The sequencing primers used here generate antisense sequences, except
primer JEJ- 1 which generates sense sequences with PCR-product I R.
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Figure 1. Autoradiogram of a DNA sequencing gel. To facilitate the interpretation of results, G reactions from six (lanes 1-6) different individ-
uals were loaded adjacent to each other, followed by A, T, and C reactions, in this order, from the same individuals. Lane T4 has an extra band
(arrow), indicating the presence ofG to T change in one allele of cell line JIMM498. The sequence is in antisense orientation.
the aorta. Two patients had iliac artery aneurysms. Six individ-
uals with abdominal or thoracic aortic aneurysms had one or
more family members with intracranial aneurysms. At the
time ofthe diagnosis the aortic aneurysm had ruptured in 7/54
patients. 36 patients underwent an elective operation for their
aortic aneurysms. Five patients were first diagnosed by ultra-
sonographic examination.
DNA sequences and polymorphisms of type III collagen.
The sequence analysis carried out here provided 3,232 nucleo-
tides from each allele of the gene for type III procollagen. The
region analyzed covered the coding sequences for all the 14
amino acids of the amino-terminal telopeptide, all the 1,029
amino acids ofthe triple-helical domain, all the 25 amino acids
of the carboxyterminal telopeptide, and 8 of the 246 amino
acids of the carboxy-terminal propeptide. The sequences for
the amino-terminal propeptide and most of the carboxy-ter-
minal propeptide were not analyzed. These amino acid se-
quences are cleaved off from the procollagen before the fibril
formation can occur and they are, therefore, not present in the
mature form of collagen (20).
Only two sequence variations were found in the 54 individ-
uals (Table IV). Cell line JIMM407 had a G to A change at nt
907. The nucleotide change converted the codon at amino acid
position 136 from GGG for glycine to AGG, a codon for argi-
nine. The mutation was confirmed using genomic DNA iso-
lated from the patient's fibroblasts (not shown). The mutation
was not found in any of additional 127 individuals sequenced
in the laboratory.
The patient was an 18-yr-old black male without any prior
relevant medical history (43). He had suddenly developed par-
aparesis and bilateral loss of pulses below the waist (43). An
aortogram disclosed a dissecting aneurysm of the entire aorta
and obstruction ofblood flow below the renal arteries (43). His
autopsy findings revealed dissecting aortic aneurysm and gener-
alized fibromuscular dysplasia (43). His father had died at the
age of 36 yr in a car accident and no affected relatives were
available for DNA testing. His mother did not have the muta-
tion, but the patient's three unaffected sibs were found to have
the same mutation. Ultrasound examination of the aorta on
the sibs (aged 21, 20, and 16 yr) did not reveal any abnormali-
ties.
In the cell line JIMM498 a C to A change was found at nt
2002, changing the codon CCT for proline at amino acid posi-
tion 501 to ACT, a codon for threonine (Fig. 1 ). PCR on geno-
mic DNA from the patient indicated that the sequence variant
was real and not a PCR artifact (not shown). The change was
not found in any of the other 127 individuals sequenced in the
laboratory. The patient was 70 yr old, when he was operated on
for an abdominal aortic aneurysm. His father also had an aortic
aneurysm but was deceased and no material was available for
DNA testing. The patient's nephew (a son of the patient's
younger brother) was operated on for an intracranial aneurysm
at the age of28 yr. This nephew had the mutation. DNA analy-
sis revealed that the change was also present in the patient's two
unaffected brothers aged 68 and 73 yr, the younger of which
had been examined by sonography and no aortic aneurysm was
found. Thus, two unaffected and two affected individuals in
the family had the DNA change. The change was, therefore,
probably not the cause of the aneurysms.
When analyzing the sequencing results from the 54 individ-
Aortic Aneurysms and Type III Procollagen Gene 2543
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Table IV. Sequence Variations Detected in the 54 Patients
Cell line
code Location* Naturet Occurrence
JIMM407 nt 907 (E14) Glyl36 -Arg 1/128§
JIMM498 nt 2002 (E30) Pro501 - Thr I/128§
* E14, exon 14 of the gene for type III procollagen; E30, exon 30 of
the gene for type III procollagen.
$ Numbering starts at the beginning of the triple-helical domain of
type III procollagen.
§ Only one patient was found to have the base change. A total of 127
other unrelated individuals that included the 49 other aortic aneu-
rysm patients presented here, 55 patients with intracranial aneurysms,
5 patients with the EDS type IV, 4 patients with osteogenesis imper-
fecta, 5 patients with the EDS (without subclassification), 8 patients
with a variety of connective tissue abnormalities without any specific
diagnosis, and one apparently healthy individual were sequenced in
the laboratory.
uals, special care was taken to record data on known polymor-
phic regions of the type III collagen. The three polymorphisms
that have been found previously in the coding region oftype III
collagen are at positions nt 1851 (Wu and Kuivaniemi, unpub-
lished results), 2092 (41), and 2244 (42). 40 ofthe 54 individ-
uals were found to be heterozygous for at least one of the poly-
morphisms (Table V), indicating that both of the alleles ofthe
gene for type III procollagen were expressed at the mRNA
level. The polymorphism analysis was also carried out on geno-
mic DNA samples isolated from the cultured skin fibroblasts of
the patients. The results obtained from the analysis showed
that the 40 individuals that were heterozygous in their cDNA
for one or more polymorphisms were also heterozygous in their
genomic DNA. The results also showed that the 14 individuals
who did not show any heterozygosity in the cDNA sequences
were homozygous on their genomic DNA for all three markers
studied.
Discussion
There are two general approaches using DNA techniques that
can be used to identify the gene harboring the mutations caus-
ing aortic aneurysms. The first approach is to carry out linkage
studies using markers that have been mapped to a particular
locus on the genome and are used to test whether or not the
marker is co-inherited with aortic aneurysms in families. Link-
age can be established whenever the phenotype and genotype
of related individuals is analyzed. Therefore, linkage can be
established by analyzing large families. There are, however,
Table V. Heterozygosity ofthe 54 Patients at Three Polymorphic
Sites Located in the Coding Sequences of Type III Collagen
Location of polymorphism Number of heterozygous individuals
nt 1851 18
nt 2092 22
nt 2244 21
Total number of patients heterozygous for at least one of the markers:
40.
several problems in the approach when studying a late-onset
disease such as aortic aneurysms. It is rare to find large index
families that have more than two generations ofliving, affected
members so that pertinent samples can be obtained. In addi-
tion, diagnosis is a problem, inasmuch as the data on the inci-
dence ofaneurysms in the population indicate that few individ-
uals develop aneurysms before the age of 50 yr and that the
incidence increases with age.
The second approach, the candidate gene approach, in-
volves the analysis of a candidate gene for absence or presence
of mutations. The modem techniques of molecular biology
have made the approach feasible (44). Here we were able to get
definitive results from detailed DNA sequencing analysis ofthe
gene for type III procollagen of 54 individuals from 50 unre-
lated families. The analysis revealed a mutation in obligatory
glycine (20, 21 ) in one patient. The substitution ofarginine for
a glycine at amino acid position 136 in type III procollagen is
likely to disrupt the triple-helical structure of the protein and
make the protein less stable (20, 21 ). The finding represents a
second example ofa glycine to arginine mutation in the type III
procollagen causing aortic aneurysms in patients without other
signs ofthe EDS. The first report was a substitution ofarginine
for glycine at amino acid position 619 of the triple-helical do-
main of type III procollagen (25).
The other sequence variant detected in another patient sub-
stituted threonine for proline in a Y position of the Gly-X-Y
repeat of collagen triple-helical domain (20, 21 ). Substitution
ofthreonine for a Y-position proline is not likely to be destabi-
lizing since six ofthe 14 threonines normally found in the type
III collagen triple-helical domain (36) occupy the Y position.
In addition, threonine and proline have been exchanged during
evolution of collagens (45). Also, the mutation was present in
the patient's apparently unaffected brothers suggesting that the
mutation was an infrequent sequence variant. The results,
therefore, indicate that mutations in the triple-helical domain
of type III procollagen are the cause of - 2% (1/ 50) of aortic
aneurysms. In addition, the results suggest that mutations in
the promoter region or other control regions of the gene for
type III procollagen are not a common cause for aneurysms, in
that at least 40 of the 50 patients studied here had mRNA that
was derived from both alleles of the gene.
From a theoretical perspective, DNA sequencing provides a
complete record of all of the bases that comprise a gene or its
coding sequence. Therefore, DNA sequencing will lead to the
detection of all mutations in a target region. Furthermore, it
makes it possible to exclude definitively the region from those
that possibly contain mutations. Our results demonstrate that
sequencing has become a feasible approach not only to estab-
lish rapidly and definitively whether or not a candidate gene
harbors the mutations causing a disease phenotype, but also to
determine what fraction of affected individuals have a muta-
tion in the particular candidate gene. This approach could,
therefore, be used to establish whether or not other genes that
have been suggested as candidate genes, such as the genes for
fibrillin ( 17), elastin (31 ), collagenase (26), elastase (27), or
tissue inhibitor of metalloproteinase (29), harbor mutations
causing aortic aneurysms.
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